83
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria

      1 , 2 , 3 , 4 , 1 , 5 , 6 , 6 , 7 , 8 , 1 , 9 , 10 , 11 , 7 , 8 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 1 , 18 , 21 , 22 , 23 , 24 , 25 , 10 , 26 , 1 , 27 , 16 , 28 , 1 , 29 , 30 , 6 , 31 , 1 , 32 , 32 , 33 , 34 , 35 , 36 , 36 , 37 , 36 , 35 , 38 , 1 , 1 , 27 , 16 , 39 , 18 , 40 , 41 , 42 , 43 , 1 , International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD)
      Journal of the European Academy of Dermatology and Venereology
      Wiley

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Behçet's disease (BD) is a chronic, relapsing, inflammatory vascular disease with no pathognomonic test. Low sensitivity of the currently applied International Study Group (ISG) clinical diagnostic criteria led to their reassessment. An International Team for the Revision of the International Criteria for BD (from 27 countries) submitted data from 2556 clinically diagnosed BD patients and 1163 controls with BD-mimicking diseases or presenting at least one major BD sign. These were randomly divided into training and validation sets. Logistic regression, 'leave-one-country-out' cross-validation and clinical judgement were employed to develop new International Criteria for BD (ICBD) with the training data. Existing and new criteria were tested for their performance in the validation set. For the ICBD, ocular lesions, oral aphthosis and genital aphthosis are each assigned 2 points, while skin lesions, central nervous system involvement and vascular manifestations 1 point each. The pathergy test, when used, was assigned 1 point. A patient scoring ≥4 points is classified as having BD. In the training set, 93.9% sensitivity and 92.1% specificity were assessed compared with 81.2% sensitivity and 95.9% specificity for the ISG criteria. In the validation set, ICBD demonstrated an unbiased estimate of sensitivity of 94.8% (95% CI: 93.4-95.9%), considerably higher than that of the ISG criteria (85.0%). Specificity (90.5%, 95% CI: 87.9-92.8%) was lower than that of the ISG-criteria (96.0%), yet still reasonably high. For countries with at least 90%-of-cases and controls having a pathergy test, adding 1 point for pathergy test increased the estimate of sensitivity from 95.5% to 98.5%, while barely reducing specificity from 92.1% to 91.6%. The new proposed criteria derived from multinational data exhibits much improved sensitivity over the ISG criteria while maintaining reasonable specificity. It is proposed that the ICBD criteria to be adopted both as a guide for diagnosis and classification of BD. © 2013 The Authors Journal of the European Academy of Dermatology and Venereology © 2013 European Academy of Dermatology and Venereology.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: not found
          • Article: not found

          Behçet's disease.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Epidemiology of Adamantiades-Behçet's disease.

            Adamantiades-Behçet's disease is a universal disorder with varying prevalence, i.e. 80-370 patients per 100,000 inhabitants in Turkey, 2-30 patients per 100,000 inhabitants in the Asian continent and 0.1-7.5 patients per 100,000 inhabitants in Europe and the USA. Certain ethnic groups are mainly affected, while the prevalence of the disease seems to be strongly dependent on the geographic area of their residence. These data indicate environmental triggering of a genetically determined disorder. The disease usually occurs around the third decade of life, however, early and late onsets (first year of life to 72 years) have been reported. Juvenile onset disease rates from 7 to 44% in different ethnic groups; juvenile disease is less frequent, i.e. 2-21%. Both genders are equally affected. Familial occurrence has been reported in 1-18% of the patients, mostly of Turkish, Israeli and Korean origin, and is increased in patients with juvenile disease. Oral aphthous ulcers represent the onset sign in the majority of patients worldwide (47-86%). Oral aphthous ulcers (92-100%), genital ulcerations (57-93%), skin lesions (38-99%), ocular lesions (29-100%) and arthropathy (16-84%) are the most frequent clinical features; sterile pustules (28-66%) and erythema nodosum (15-78%) are the most common encountered skin lesions. The positivity of pathergy test varies widely in different populations (6-71%). HLA-B51 is associated with high relative risk for the disease in a small geographic area of the Mediterranean Sea countries and Southern Asia. Diagnosis can be established 2 to 15 years after the onset of the disease. Male gender, early development of the disease, and HLA-B51 positivity are markers of severe prognosis (mortality rates of 0-6%).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Diagnostic value of pathergy test in Behcet's disease according to the change of incidence over the time.

              Pathergy test (PT) is used for the diagnosis of Behcet's disease (BD). It is a criterion in many classification/diagnosis criteria. PT is mainly seen in BD but can be seen in other conditions too. PT has been reported with high frequency from most countries along the Silk Road. The sensitivity of pathergy phenomenon (PP) is declining over the time. The aim of this study was to look for the diagnostic value of PT in the past and at the present time. The BD registry (Rheumatology Research Center, Tehran University of Medical Sciences) has the data of 6,607 BD and 4,292 control patients. Patients and controls were divided in four groups of 1,650 BD and 1,073 controls. Sensitivity, specificity, positive and negative predictive value (PPV-NPV), positive and negative likelihood ratio (PLR-NLR), diagnostic odds ratio (DOR), and Youden's index (YI) were calculated for each group. The first and the fourth quartiles were compared. Sensitivity of PT decreased from 64.2% (first quartile) to 35.8% (fourth quartile). Specificity improved from 86.6% to 98.4%. PPV improved from 82.7% to 95.7%. NPV decreased from 82.7% to 60.5%. PLR improved from 4.8 to 22.4, while NLR deteriorated from 0.41 to 0.65. DOR improved from 11.6 to 34.3. Yuden's index worsened from 0.5 to 0.34. Although sensitivity of PP decreased, the increase of specificity is a plus value for diagnosis. As a result, PPV, PLR, and DOR improved, while NPR, NLR, and YI deteriorated. Although the pathergy test lost its sensitivity during the past 35 years, it has not lost its value as a diagnostic test, improving many of its characteristics. In a practical view, the chances of getting a positive test have decreased over the time. However, a positive test is rather the synonym of Behcet's disease, with a probability of 98.4%.
                Bookmark

                Author and article information

                Journal
                JDV
                Journal of the European Academy of Dermatology and Venereology
                J Eur Acad Dermatol Venereol
                Wiley
                09269959
                March 2014
                March 2014
                February 26 2013
                : 28
                : 3
                : 338-347
                Affiliations
                [1 ]Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences; Tehran Iran
                [2 ]Department of Internal Medicine; Alexandria Faculty of Medicine, Alexandria University; Alexandria Egypt
                [3 ]Department of Internal Medicine; Mayo Clinic College of Medicine; Jacksonville FL USA
                [4 ]Division of Health Sciences Research; Mayo Clinic College of Medicine; Jacksonville FL USA
                [5 ]Department of Internal Medicine I; Innsbruck Medical University; Innsbruck Austria
                [6 ]Division of Evidence Based Dermatology; Dessau Medical Center; Dessau Germany
                [7 ]Departments of Dermatology, Venereology, Allergology and Immunology; Dessau Medical Center; Dessau Germany
                [8 ]German Registry of Adamantiades-Behçet's Disease; Dessau Germany
                [9 ]Department of Internal Medicine; King Faisal Specialist Hospital and Research Centre, College of Medicine, King Saud University; Riyadh Saudi Arabia
                [10 ]Department of Systemic Rheumatic Diseases; State Institute of Rheumatology; Moscow Russia
                [11 ]Department of Internal Medicine; Aga Khan University Hospital; Karachi Pakistan
                [12 ]Department of Internal Medicine; Division of Rheumatology; Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok Thailand
                [13 ]Department of Dermatology and Venereology; Innsbruck Medical University; Innsbruck Austria
                [14 ]Department of Internal Medicine; Hospital São Teotónio; Viseu Portugal
                [15 ]Department of Internal Medicine; CHU Ibn Rochd; Casablanca Morocco
                [16 ]Department of Internal Medicine; La Rabba Hospital; Tunis Tunisia
                [17 ]Department of Dermatology; School of Medicine, Ankara University; Ankara Turkey
                [18 ]Department of Internal Medicine; Hospital Geral de Santo António; Porto Portugal
                [19 ]Department of Dermatology; Chang Gung Memorial Hospital Kaohsiung, Chang Gung University; Kaohsiung Taiwan
                [20 ]Department of Internal Medicine; Hadassah-Hebrew University Medical Centre; Jerusalem Israel
                [21 ]Department of Internal Medicine; Coimbra University Hospital; Coimbra Portugal
                [22 ]Department of Internal Medicine; Hospital de S. João; Porto Portugal
                [23 ]Department of Rheumatology and Immunology; Peking Union Medical College Hospital; Beijing China
                [24 ]Department of Medicine II; Fernando da Fonseca Hospital; Lisbon Portugal
                [25 ]Kadisia Clinic; Tripoli Libya
                [26 ]Rheumatology Unit; Hospital Juan Canalejo; La Coruña Spain
                [27 ]Department of Dermatology and Venereology; College of Medicine, Medical City Teaching Hospital, University of Baghdad; Baghdad Iraq
                [28 ]Department of Therapeutic Dentistry; Azerbaijan Medical University; Baku Azerbaijan
                [29 ]Department of Rheumatology; Medical Center; Athens Greece
                [30 ]Department of Internal Medicine; Clinical Immunology and Rheumatology Service; All India Institute of Medical Sciences; New Delhi India
                [31 ]Department of Internal Medicine; Jordan Hospital; Amman Jordan
                [32 ]Department of Ophthalmology and Visual Sciences; Hokkaido University Graduate School of Medicine; Sapporo Japan
                [33 ]Rheumatology Department of Lucania; San Carlo Hospital, Potenza and Madonna delle Grazie Hospital, Matera; Italy
                [34 ]Portuguese Institute of Rheumatology; Lisbon Portugal
                [35 ]Rheumatology Unit; Hospital Santa Maria Nuova; Reggio Emilia Italy
                [36 ]Department of Rheumatology and Metabolic Bone Diseases; Hospital Santa Maria; Lisbon Portugal
                [37 ]Rheumatology Research Unit, Institute of Molecular Medicine, Medical Faculty, University of Lisbon; Lisbon Portugal
                [38 ]Department of Internal Medicine; Santo António dos Capuchos Hospital; Lisbon Portugal
                [39 ]Department of Internal Medicine; Hospital Espírito Santo; Évora Portugal
                [40 ]Department of Internal Medicine; Hospital Sousa Martins; Guarda Portugal
                [41 ]Internal Medicine Department; Pitie Salpetriere Hospital; Paris France
                [42 ]Allergy, Arthritis and Rheumatism Clinic, Gleneagles Medical Centre; Singapore Singapore
                [43 ]Rheumatology and Clinical Immunology Department; Peking University First Hospital; Peking China
                Article
                10.1111/jdv.12107
                23441863
                c3ddfa6b-a931-4ebb-aabf-a585778b1757
                © 2013

                http://doi.wiley.com/10.1002/tdm_license_1.1

                http://onlinelibrary.wiley.com/termsAndConditions#vor

                History

                Comments

                Comment on this article